On July 23, 2025, N2OFF, Inc. amended its agreement to acquire MitoCareX Bio Ltd., specifying 32,808,629 shares of common stock and extending the agreement's deadline by 90 days. This filing updates key details of the merger process, which originally began on February 24, 2025.